Sanara MedTech Q2 2026 Earnings Report

Sanara MedTech EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.07
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Sanara MedTech Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $28.50 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Sanara MedTech Announcement Details

• Quarter: Q2 2026
• Date: 8/12/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, August 12, 2026
• Conference Call Time: 8:00AM ET

Sanara MedTech (NASDAQ:SMTI) is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies. The company offers a range of balloon-based dilation products, including multi­sinus dilation systems, as well as adjunctive instruments for tissue access and endoscopic visualization. Its ENT platform is complemented by specialized energy‐based ablation technologies and implantable devices designed to address complex nasal and ear disorders.

Following its establishment through a business combination in early 2022, Sanara MedTech continues to invest in clinical studies and product enhancements aimed at broadening indications and improving procedural efficiency. The company collaborates with leading physicians and academic centers to validate its technologies and expand training programs that support adoption by surgeons worldwide.

Headquartered in Irvine, California, Sanara MedTech serves markets across North America, Europe, Latin America and Asia Pacific through a combination of direct sales teams and distributor partnerships. Its leadership team comprises experienced executives and clinicians with backgrounds in medical device innovation, regulatory affairs and global commercialization. Looking forward, the company is positioned to leverage its established technology platforms to pursue growth opportunities in ENT and adjacent specialties.